Catalent Inc. (CTLT), a leading provider of advanced delivery technologies, has reportedly missed their Q3 Revenue estimates while also reporting a loss. On the brighter side, the company has received an acquisition offer from Novo Holdings, pushing the stock price up 10%. The Federal Trade Commission (FTC) has requested more information about this acquisition, which is slated to be a $16.5 billion deal. Adding to its strategic moves, Catalent has partnered to accelerate clinical trial timelines and inked deals for new and effective drug delivery. Share purchases by Nomura Holdings Inc. and Victory Capital Management Inc. indicate investor confidence. However, Catalent’s quarter earnings have consistently lagged estimates, taking a toll on the share prices. Despite these headwinds, Catalent has been showing strength in its stock and was able to close deals to boost its financial standing, such as the $4.8 billion private debt led by Ares and Blue Owl. However, a possible delay in Q1 results and the receipt of a third request from FTC raised skeptics among investors. The company also faced a shareholder lawsuit accusing it of misleading investors. Despite the ups and downs, Novo Holdings' parent company has ultimately secured the acquisition of Catalent to boost Wegovy supply for $16.5 billion.
Catalent CTLT News Analytics from Fri, 20 Jan 2023 08:00:00 GMT to Tue, 21 May 2024 20:14:11 GMT -
Rating 3
- Innovation 1
- Information 8
- Rumor -3
